CAR T cell therapy targeting CD19 has demonstrated significant tissue-based B cell depletion, improving outcomes in autoimmune models such as lupus by reducing autoantibody levels and disease symptoms. The gene discussed is CD19; the disease is systemic lupus erythematosus.